In the final data review, prior to the un-blinding of the study data, ResApp identified at least two issues with the clinical data. Contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. A high number of recordings were also found to contain a second person’s cough sounds or an unacceptable amount of background noise and interference. These issues are known to affect cough sound analysis and their presence has skewed these preliminary results.
I think they can still recover from this. You all need to remember that this is only the initial trial. They can always adapt and create better algorithm and condition for the next trial. No point in selling now that it has gone down by 80%. Might as well just see how things will go from here
- Forums
- ASX - By Stock
- RAP
- Ann: Preliminary Top-line Results from SMARTCOUGH-C Study
Ann: Preliminary Top-line Results from SMARTCOUGH-C Study, page-217
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online